Logo image of MDGL

MADRIGAL PHARMACEUTICALS INC (MDGL) Stock Fundamental Analysis

NASDAQ:MDGL - Nasdaq - US5588681057 - Common Stock - Currency: USD

278.23  +4.13 (+1.51%)

After market: 278.23 0 (0%)

Fundamental Rating

3

Overall MDGL gets a fundamental rating of 3 out of 10. We evaluated MDGL against 558 industry peers in the Biotechnology industry. MDGL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. MDGL is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

MDGL had negative earnings in the past year.
MDGL had a negative operating cash flow in the past year.
MDGL had negative earnings in each of the past 5 years.
In the past 5 years MDGL always reported negative operating cash flow.
MDGL Yearly Net Income VS EBIT VS OCF VS FCFMDGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M -400M

1.2 Ratios

The Return On Assets of MDGL (-36.49%) is comparable to the rest of the industry.
MDGL's Return On Equity of -50.39% is fine compared to the rest of the industry. MDGL outperforms 65.59% of its industry peers.
Industry RankSector Rank
ROA -36.49%
ROE -50.39%
ROIC N/A
ROA(3y)-61.5%
ROA(5y)-68.68%
ROE(3y)-101.19%
ROE(5y)-102.23%
ROIC(3y)N/A
ROIC(5y)N/A
MDGL Yearly ROA, ROE, ROICMDGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K -1.5K

1.3 Margins

The Gross Margin of MDGL (96.61%) is better than 96.59% of its industry peers.
MDGL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 96.61%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MDGL Yearly Profit, Operating, Gross MarginsMDGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

More info and screens

5

2. Health

2.1 Basic Checks

MDGL does not have a ROIC to compare to the WACC, probably because it is not profitable.
MDGL has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, MDGL has more shares outstanding
The debt/assets ratio for MDGL has been reduced compared to a year ago.
MDGL Yearly Shares OutstandingMDGL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
MDGL Yearly Total Debt VS Total AssetsMDGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

An Altman-Z score of 10.04 indicates that MDGL is not in any danger for bankruptcy at the moment.
The Altman-Z score of MDGL (10.04) is better than 86.92% of its industry peers.
MDGL has a Debt/Equity ratio of 0.15. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.15, MDGL is doing worse than 68.28% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Altman-Z 10.04
ROIC/WACCN/A
WACC9.55%
MDGL Yearly LT Debt VS Equity VS FCFMDGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M

2.3 Liquidity

MDGL has a Current Ratio of 5.98. This indicates that MDGL is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of MDGL (5.98) is better than 60.93% of its industry peers.
MDGL has a Quick Ratio of 5.93. This indicates that MDGL is financially healthy and has no problem in meeting its short term obligations.
MDGL has a better Quick ratio (5.93) than 61.47% of its industry peers.
Industry RankSector Rank
Current Ratio 5.98
Quick Ratio 5.93
MDGL Yearly Current Assets VS Current LiabilitesMDGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

4

3. Growth

3.1 Past

MDGL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.83%, which is quite impressive.
EPS 1Y (TTM)21.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.01%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, MDGL will show a very strong growth in Earnings Per Share. The EPS will grow by 42.47% on average per year.
Based on estimates for the next years, MDGL will show a very strong growth in Revenue. The Revenue will grow by 83.57% on average per year.
EPS Next Y41.56%
EPS Next 2Y42.83%
EPS Next 3Y43.52%
EPS Next 5Y42.47%
Revenue Next Year291.36%
Revenue Next 2Y153.17%
Revenue Next 3Y119.26%
Revenue Next 5Y83.57%

3.3 Evolution

MDGL Yearly Revenue VS EstimatesMDGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B 5B
MDGL Yearly EPS VS EstimatesMDGL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 50 100

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MDGL. In the last year negative earnings were reported.
MDGL is valuated quite expensively with a Price/Forward Earnings ratio of 314.72.
Based on the Price/Forward Earnings ratio, MDGL is valued cheaper than 87.63% of the companies in the same industry.
MDGL is valuated expensively when we compare the Price/Forward Earnings ratio to 22.25, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 314.72
MDGL Price Earnings VS Forward Price EarningsMDGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 100 200 300

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MDGL Per share dataMDGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20 30

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates MDGL does not grow enough to justify the current Price/Earnings ratio.
MDGL's earnings are expected to grow with 43.52% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y42.83%
EPS Next 3Y43.52%

More info and screens

0

5. Dividend

5.1 Amount

MDGL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MADRIGAL PHARMACEUTICALS INC

NASDAQ:MDGL (6/6/2025, 8:07:35 PM)

After market: 278.23 0 (0%)

278.23

+4.13 (+1.51%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-01 2025-05-01/bmo
Earnings (Next)08-05 2025-08-05/bmo
Inst Owners96.65%
Inst Owner Change2.64%
Ins Owners5.45%
Ins Owner Change6.46%
Market Cap6.18B
Analysts82.73
Price Target430.37 (54.68%)
Short Float %21.11%
Short Ratio11.8
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)24.55%
Min EPS beat(2)11.7%
Max EPS beat(2)37.4%
EPS beat(4)4
Avg EPS beat(4)21.71%
Min EPS beat(4)7.5%
Max EPS beat(4)37.4%
EPS beat(8)4
Avg EPS beat(8)7.46%
EPS beat(12)5
Avg EPS beat(12)3.88%
EPS beat(16)8
Avg EPS beat(16)3.93%
Revenue beat(2)2
Avg Revenue beat(2)10.53%
Min Revenue beat(2)2.78%
Max Revenue beat(2)18.28%
Revenue beat(4)4
Avg Revenue beat(4)91.76%
Min Revenue beat(4)2.78%
Max Revenue beat(4)267.7%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.9%
PT rev (3m)10.8%
EPS NQ rev (1m)-20.77%
EPS NQ rev (3m)-9.55%
EPS NY rev (1m)0.09%
EPS NY rev (3m)6.41%
Revenue NQ rev (1m)17.2%
Revenue NQ rev (3m)28.48%
Revenue NY rev (1m)16.55%
Revenue NY rev (3m)33.33%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 314.72
P/S 19.46
P/FCF N/A
P/OCF N/A
P/B 7.95
P/tB 8
EV/EBITDA N/A
EPS(TTM)-18.05
EYN/A
EPS(NY)0.88
Fwd EY0.32%
FCF(TTM)-18.08
FCFYN/A
OCF(TTM)-17.81
OCFYN/A
SpS14.3
BVpS35.01
TBVpS34.79
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -36.49%
ROE -50.39%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 96.61%
FCFM N/A
ROA(3y)-61.5%
ROA(5y)-68.68%
ROE(3y)-101.19%
ROE(5y)-102.23%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.3
Health
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 467.1%
Cap/Sales 1.92%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.98
Quick Ratio 5.93
Altman-Z 10.04
F-Score5
WACC9.55%
ROIC/WACCN/A
Cap/Depr(3y)305.68%
Cap/Depr(5y)207.7%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.01%
EPS Next Y41.56%
EPS Next 2Y42.83%
EPS Next 3Y43.52%
EPS Next 5Y42.47%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year291.36%
Revenue Next 2Y153.17%
Revenue Next 3Y119.26%
Revenue Next 5Y83.57%
EBIT growth 1Y6.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year28.21%
EBIT Next 3Y40.7%
EBIT Next 5YN/A
FCF growth 1Y-54.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-52.62%
OCF growth 3YN/A
OCF growth 5YN/A